ArticleHepatology communications2025

Semaglutide for metabolic dysfunction-associated steatohepatitis (MASH): Estimating eligibility from the 2021-2023 National Health and Nutrition Examination Survey (NHANES).

Joel W Hughes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.